{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:08:10Z","timestamp":1789157290914,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,9]],"date-time":"2027-09-09T00:00:00Z","timestamp":1820448000000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100020620","name":"University Hospitals of the Great West Health Cooperation Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013018","name":"Hospital for Special Surgery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014269","name":"Philippe Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031376","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24AR08217"],"award-info":[{"award-number":["K24AR08217"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K01AI163412"],"award-info":[{"award-number":["K01AI163412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ard.2026.02.017","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:14:45Z","timestamp":1775823285000},"page":"1879-1889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-379X","authenticated-orcid":false,"given":"Deanna P","family":"Jannat-Khah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankti","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawnie J","family":"Braaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minerva","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiko R","family":"Katsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Tison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmela","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilasha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami A","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.02.017_bib0001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2026.02.017_bib0002","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.017_bib0003","doi-asserted-by":"crossref","first-page":"e2002","DOI":"10.1002\/onco.13918","article-title":"Real-world clinical and economic outcomes in selected immune-related adverse events among patients with cancer receiving immune checkpoint inhibitors","volume":"26","author":"Zheng","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ard.2026.02.017_bib0004","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ard.2026.02.017_bib0005","doi-asserted-by":"crossref","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2026.02.017_bib0006","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.017_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ard.2026.02.017_bib0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ard.2026.02.017_bib0010","doi-asserted-by":"crossref","first-page":"612","DOI":"10.55563\/clinexprheumatol\/o5nvgv","article-title":"Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre","volume":"39","author":"Gonzalez-Maz\u00f3n","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"#cr-split#-10.1016\/j.ard.2026.02.017_bib0011.1","unstructured":"NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. In: Journal of the National Comprehensive Cancer Network. Vol. 22, Issue 9. 2024 [updated 2026 Mar 18"},{"key":"#cr-split#-10.1016\/j.ard.2026.02.017_bib0011.2","unstructured":"cited 2025 Sep 3]. Available from: https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/9\/article-p582.xml"},{"key":"10.1016\/j.ard.2026.02.017_bib0012","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ard.2026.02.017_bib0013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.017_bib0014","article-title":"Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study","volume":"22","author":"Costa Svedman","year":"2024","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.ard.2026.02.017_bib0015","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ard.2026.02.017_bib0016","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/1078155219872786","article-title":"The impact of corticosteroid use during anti-PD1 treatment","volume":"26","author":"Pan","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ard.2026.02.017_bib0017","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.21037\/tlcr-20-635","article-title":"Exploring the immune-checkpoint inhibitors\u2019 efficacy\/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease","volume":"10","author":"Passiglia","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ard.2026.02.017_bib0018","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ard.2026.02.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ard.2026.02.017_bib0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00262-024-03772-9","article-title":"Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent","volume":"73","author":"Albarr\u00e1n","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"#cr-split#-10.1016\/j.ard.2026.02.017_bib0021.1","unstructured":"National Cancer Institute. CTCAE and adverse event Reporting [Internet]. 2025 [updated 2026 Mar 18"},{"key":"#cr-split#-10.1016\/j.ard.2026.02.017_bib0021.2","unstructured":"cited 2025 Sep 3]. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events"},{"key":"10.1016\/j.ard.2026.02.017_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102452","article-title":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias","volume":"110","author":"Kfoury","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ard.2026.02.017_bib0023","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ard.2026.02.017_bib0024","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/imj.16629","article-title":"Comparative study of management strategies for immune checkpoint inhibitor-induced inflammatory arthritis: rheumatologists versus oncologists","volume":"55","author":"Yoon","year":"2025","journal-title":"Intern Med J"},{"key":"10.1016\/j.ard.2026.02.017_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2494433","article-title":"Impact of steroid dose and timing on efficacy of combination PD-1\/CTLA-4 blockade","volume":"14","author":"Curkovic","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ard.2026.02.017_bib0026","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ard.2026.02.017_bib0027","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ard.2026.02.017_bib0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41574-025-01102-2","article-title":"Steroid hormones as modulators of anti-tumoural immunity","volume":"21","author":"Schwarzlmueller","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ard.2026.02.017_bib0029","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","article-title":"Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"145","author":"Skribek","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ard.2026.02.017_bib0030","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ard.2026.02.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ard.2026.02.017_bib0032","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis","volume":"13","author":"Dall\u2019Olio","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ard.2026.02.017_bib0033","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-22-0495","article-title":"The timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example","volume":"31","author":"Duchesneau","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ard.2026.02.017_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011545","article-title":"Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study","volume":"13","author":"Quandt","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ard.2026.02.017_bib0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2026.02.017_bib0036","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamadermatol.2019.3353","article-title":"Age-specific incidence of melanoma in the United States","volume":"156","author":"Paulson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ard.2026.02.017_bib0037","unstructured":"American Cancer Society. Cancer facts & figures 2025 [Internet]. [updated 2026 Mar 18; cited 2025 Mar 2]. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2025-cancer-facts-figures.html"},{"key":"10.1016\/j.ard.2026.02.017_bib0038","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/bjc.2013.246","article-title":"The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987-2009: a registry-based cohort study","volume":"109","author":"Grann","year":"2013","journal-title":"Br J Cancer"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672600097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672600097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:23Z","timestamp":1789154423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672600097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S000349672600097X"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.017","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}